Browsing Tag
Haleon plc
4 posts
Haleon (HLN) Q1 2026 results: Can Sensodyne and parodontax offset weak cold and flu demand?
Haleon’s cold and flu drag is testing growth. Sensodyne, parodontax and margin discipline may decide whether HLN can regain momentum.
Haleon (NYSE, LSE: HLN) bets on China’s oral health boom with £65m Shanghai manufacturing facility
Haleon invests £65M in a Shanghai oral health plant to expand Sensodyne and parodontax across China. Discover what this move signals for the global oral care market.
Haleon plc (LON: HLN) FY2025 results: Can margin expansion, operating model reform, and capital discipline overcome weak North American demand?
Haleon plc posts 3% organic growth and 10.5% profit expansion in FY2025. Can margin gains and buybacks drive stronger returns in 2026? Read more.
Haleon to repurchase £170M in shares as Pfizer completes exit
Haleon repurchases £170M in shares as Pfizer exits its stake. Find out how this impacts stock performance, investor sentiment, and future growth.